COVID-19: What you need to know

Idrissi, Hossam Hilal El

doi:10.1016/j.genrep.2020.100756

Cited by 14 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studying the mutations in SARS-CoV-2 ( Center for Disease Control and Prevention (CDC), n.d. ; Saha et al, 2020 ; Dorp et al, 2020 ; Khailany et al, 2020 ; Junejo et al, 2020 ) 5. Studying the virus in connection with the COVID-19 disease (for example, for drugs, treatment, and vaccine) ( Center for Disease Control and Prevention (CDC), n.d. ; Mirza and Froeyen, 2020 ; Tai et al, 2020 ; Emameh et al, 2020 ; Junejo et al, 2020 ) Note: Literature and publications related to the COVID-19 disease and pandemic (see Junejo et al, 2020 ; El Idrissi, 2020 ; Rothan and Byrareddy, 2020 ; Wilder-Smith et al, 2020 ; Anastassopoulou et al, 2020 ) are mainly interested in the disease outbreak data analysis, timeline and infection rate analysis, pandemic declining prediction, etc. ( Junejo et al, 2020 ; El Idrissi, 2020 ; Rothan and Byrareddy, 2020 ; Wilder-Smith et al, 2020 ; Anastassopoulou et al, 2020 ).…”

Section: Background and Related Workmentioning

confidence: 99%

“… Note: Literature and publications related to the COVID-19 disease and pandemic (see Junejo et al, 2020 ; El Idrissi, 2020 ; Rothan and Byrareddy, 2020 ; Wilder-Smith et al, 2020 ; Anastassopoulou et al, 2020 ) are mainly interested in the disease outbreak data analysis, timeline and infection rate analysis, pandemic declining prediction, etc. ( Junejo et al, 2020 ; El Idrissi, 2020 ; Rothan and Byrareddy, 2020 ; Wilder-Smith et al, 2020 ; Anastassopoulou et al, 2020 ). …”

Section: Background and Related Workmentioning

confidence: 99%

See 1 more Smart Citation

Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2

Almubaid

Al-Mubaid

2021

Gene Reports

View full text Add to dashboard Cite

We present an analysis and comparison study of genetic variants and mutations of about 1200 genomes of SARS-CoV-2 virus sampled across the first seven months of 2020. The study includes 12 sets of about 100 genomes each collected between January and September . We analyzed the mutations, mutation frequency and count trends over time, and genomes trends over time from January through September. We show that certain mutations in the SARS-CoV-2 genome are not occurring randomly as it has been commonly believed. This finding is in agreement with other recently published research in this domain. Therefore, this validates other findings in this direction. This study includes approximately 1000 genomes and was able to identify over 35 different mutations most of which are common to almost all genomes groups. Some mutations' ratios (frequency percentage) fluctuate over time to adapt the virus to various environmental factors, climate, and populations. One of the interesting findings in this paper is that the coding region, at the nucleotide level for NSP13 protein is relatively conserved compared with other protein regions in the ORF1ab gene which makes this protein a good candidate for developing drug targets and treatment for the COVID-19 disease. Although this outcome was already reported by other researchers, we corroborated their result with our work in a different approach and another experimental setting with almost one thousand complete genome sequences. We presented and discussed all these results and findings with tables of results and illustrating figures.

show abstract

Section: Background and Related Workmentioning

confidence: 99%

Section: Background and Related Workmentioning

confidence: 99%

Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2

Almubaid

Al-Mubaid

2021

Gene Reports

View full text Add to dashboard Cite

show abstract

“…SARS‐CoV‐2 is a single‐stranded and positive‐sense RNA genome whose size is approximately equal to ∼30 kb [4] . The genome codes for accessory, non‐structural, and structural proteins (spike [S], envelope [E], membrane [M], and nucleocapsid [N]) [3a,5] …”

Section: Introductionmentioning

confidence: 99%

“…[4] The genome codes for accessory, non‐structural, and structural proteins (spike [S], envelope [E], membrane [M], and nucleocapsid [N]). [ 3a , 5 ]…”

Section: Introductionmentioning

confidence: 99%

Preliminary Structural Data Revealed That the SARS‐CoV‐2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity

et al. 2021

View full text Add to dashboard Cite

The evolution of new SARS‐CoV‐2 variants around the globe has made the COVID‐19 pandemic more worrisome, further pressuring the health care system and immunity. Novel variations that are unique to the receptor‐binding motif (RBM) of the receptor‐binding domain (RBD) spike glycoprotein, i. e. L452R‐E484Q, may play a different role in the B.1.617 (also known as G/452R.V3) variant's pathogenicity and better survival compared to the wild type. Therefore, a thorough analysis is needed to understand the impact of these mutations on binding with host receptor (RBD) and to guide new therapeutics development. In this study, we used structural and biomolecular simulation techniques to explore the impact of specific mutations (L452R‐E484Q) in the B.1.617 variant on the binding of RBD to the host receptor ACE2. Our analysis revealed that the B.1.617 variant possesses different dynamic behaviours by altering dynamic‐stability, residual flexibility and structural compactness. Moreover, the new variant had altered the bonding network and structural‐dynamics properties significantly. MM/GBSA technique was used, which further established the binding differences between the wild type and B.1.617 variant. In conclusion, this study provides a strong impetus to develop novel drugs against the new SARS‐CoV‐2 variants.

show abstract

“…Furthermore, it has been genetically linked to the bat CoVs; however, the genetic diversity suggests that the virus spillover occurred in late 2019 and an intermediate host is possibly involved [11] , [12] , [13] . Nonetheless, a mutational study clarified all these doubts and discovered additional information on SARS-CoV-2 transmission and assisted to trace its propagation [14] , [15] . As an intermediary host for SARS-CoV-2 spread to humans, pangolins have been elusively reported to play a significant role [16] .…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines

Khan

Ali

et al. 2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its new variants reported in different countries have posed a serious threat to human health and social fabrics worldwide. In addition, these new variants hindered the efforts of vaccines and other therapeutic developments. In this review article, we explained the emergence of new variants of SARS-CoV-2, their transmission risk, mortality rate, and, more importantly, the impact of each new variant on the efficacy of the developed vaccines reported in different literature and findings. The literature reported that with the emergence of new variants, the efficacy of different vaccines is declined, hospitalization is increased while the risk of reinfection also increased. The reports concluded that the emergence of a variant that entirely evades the immune response triggered by the vaccine is improbable. The emergence of new variants and reports of re-infections are creating a more distressing situation and therefore demands further investigation to formulate an effective therapeutic strategy.

show abstract

COVID-19: What you need to know

Cited by 14 publications

References 35 publications

Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2

Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2

Preliminary Structural Data Revealed That the SARS‐CoV‐2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity

SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines

Contact Info

Product

Resources

About